PE20080974A1 - Nuevas pirozolopirimidinas como inhibidores de quinasa dependientes de ciclina - Google Patents

Nuevas pirozolopirimidinas como inhibidores de quinasa dependientes de ciclina

Info

Publication number
PE20080974A1
PE20080974A1 PE2007001331A PE2007001331A PE20080974A1 PE 20080974 A1 PE20080974 A1 PE 20080974A1 PE 2007001331 A PE2007001331 A PE 2007001331A PE 2007001331 A PE2007001331 A PE 2007001331A PE 20080974 A1 PE20080974 A1 PE 20080974A1
Authority
PE
Peru
Prior art keywords
pyrimidine
cycline
dependent kinase
pyrozolopyrimidines
pirazolo
Prior art date
Application number
PE2007001331A
Other languages
English (en)
Inventor
Timothy J Guzi
Michael P Dwyer
Marc Labroli
Kartik M Keertikar
Kamil Paruch
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of PE20080974A1 publication Critical patent/PE20080974A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

SE REFIERE A UN COMPUESTO DERIVADO DE PIRAZOLO[1,5-a]PIRIMIDINA SELECCIONADA DE 3-(TIAZOL-4-IL)-5-(PIPERAZIN-3-IL)-6-BROMO-7-AMINO-PIRAZOLO[1,5-a]PIRIMIDINA; 3-(1-METIL-PIRAZOL-4-IL)-5-(PIPERAZIN-3-IL)-6-IODO-7-AMINO-PIRAZOLO[1,5-a]PIRIMIDINA; 3-(1-METILPIRAZOL-4-IL)-5-(1-AMINOCICLOPENTIL-3-IL)-6-BROMO-7-AMINO-PIRAZOLO[1,5-a]PIRIMIDINA; ENTRE OTROS. DICHOS COMPUESTOS SON INHIBIDORES DE QUINASA DEPENDIENTE DE CICLINA CDK1, CDK2, CDK9, UTILES EN EL TRATAMIENTO DE UNA ENFERMEDAD PROLIFERATIVA SELECCIONADA DE CANCER DE VEJIGA, MAMA, COLON, RINON, HIGADO, PULMON, OVARIO, ENTRE OTROS
PE2007001331A 2006-10-04 2007-10-02 Nuevas pirozolopirimidinas como inhibidores de quinasa dependientes de ciclina PE20080974A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US11/542,920 US7605155B2 (en) 2002-09-04 2006-10-04 Substituted pyrazolo[1,5-a]pyrimidines as protein kinase inhibitors

Publications (1)

Publication Number Publication Date
PE20080974A1 true PE20080974A1 (es) 2008-07-19

Family

ID=39111854

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2007001331A PE20080974A1 (es) 2006-10-04 2007-10-02 Nuevas pirozolopirimidinas como inhibidores de quinasa dependientes de ciclina

Country Status (10)

Country Link
US (1) US7605155B2 (es)
EP (1) EP2069349B1 (es)
JP (1) JP2010505839A (es)
CN (1) CN101573363B (es)
AR (1) AR063096A1 (es)
CA (1) CA2665127A1 (es)
CL (1) CL2007002856A1 (es)
PE (1) PE20080974A1 (es)
TW (1) TW200821313A (es)
WO (1) WO2008045267A2 (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5152922B2 (ja) * 2005-10-06 2013-02-27 メルク・シャープ・アンド・ドーム・コーポレーション プロテインキナーゼを阻害するためのピラゾロ［１，５−ａ］ピリミジン誘導体の使用およびプロテインキナーゼを阻害する方法
WO2007139732A1 (en) * 2006-05-22 2007-12-06 Schering Corporation Pyrazolo [1, 5-a] pyrimidines as cdk inhibitors
PE20110063A1 (es) 2008-06-20 2011-02-16 Genentech Inc DERIVADOS DE [1, 2, 4]TRIAZOLO[1, 5-a]PIRIDINA COMO INHIBIDORES DE JAK
MX2010014005A (es) * 2008-06-20 2011-02-15 Genentech Inc Compuestos de triazolopiridina inhibidores de jak y los metodos.
WO2011028638A1 (en) 2009-09-04 2011-03-10 Schering Corporation Modulators of cell cycle checkpoints and their use in combination with checkpoint kinase inhibitors
WO2011049625A1 (en) 2009-10-20 2011-04-28 Mansour Samadpour Method for aflatoxin screening of products
CA3022722A1 (en) 2009-11-05 2011-05-12 Rhizen Pharmaceuticals S.A. Pi3k protein kinase modulators
WO2011090935A1 (en) * 2010-01-19 2011-07-28 Merck Sharp & Dohme Corp. PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS mTOR INHIBITORS
WO2011119457A1 (en) * 2010-03-26 2011-09-29 Schering Corporation Process for synthesizing 6-bromo-3-(1-methyl-1h-pyrazol-4-yl)-5-(3(r)-piperidinyl)pyrazolo[1,5-a]pyrimidin-7-amine
US8883801B2 (en) 2010-08-23 2014-11-11 Merck Sharp & Dohme Corp. Substituted pyrazolo[1,5-a]pyrimidines as mTOR inhibitors
EP2608668B1 (en) * 2010-08-23 2016-06-01 Merck Sharp & Dohme Corp. Fused tricyclic inhibitors of mammalian target of rapamycin
EA024842B9 (ru) 2011-05-04 2017-08-31 Ризен Фармасьютикалз Са Соединения в качестве модуляторов протеинкиназы pi3k
DK3260455T3 (da) 2012-07-04 2019-06-11 Rhizen Pharmaceuticals S A Selektive pi3k delta-hæmmere
AU2013344716B2 (en) 2012-11-16 2018-03-01 University Health Network Pyrazolopyrimidine compounds
LT3033086T (lt) * 2013-08-14 2021-12-27 Novartis Ag Kombinuota terapija vėžiui gydyti
US9505767B2 (en) 2013-09-05 2016-11-29 Genentech, Inc. Pyrazolo[1,5-A]pyrimidin-7(4H)-onehistone demethylase inhibitors
CN106727474A (zh) * 2017-01-04 2017-05-31 仪修南 苯氧乙酸类除草剂作为化学治疗剂治疗疾病的应用
CN108653282B (zh) * 2018-06-28 2020-08-14 中国科学院昆明植物研究所 苯并噻唑类及苯并吡咯类化合物在制备抗肿瘤药物中的应用
EP3866789A4 (en) * 2018-10-15 2022-07-06 Nimbus Lakshmi, Inc. TYK2 INHIBITORS AND USES THEREOF
CN112996790B (zh) * 2018-10-30 2023-11-03 克洛诺斯生物公司 用于调节cdk9活性的化合物、组合物和方法
CN111393447B (zh) * 2020-05-14 2021-01-15 苏州信诺维医药科技有限公司 一种嘧啶并吡唑类化合物、其制备方法及应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP0302991A3 (en) 2000-09-15 2009-10-28 Vertex Pharma Isoxazoles and their use as inhibitors of erk and pharmaceutical compositions containing the compounds
CN1880317B (zh) * 2002-09-04 2012-10-10 先灵公司 作为细胞周期蛋白依赖性激酶抑制剂的吡唑并嘧啶
WO2004022559A1 (en) * 2002-09-04 2004-03-18 Schering Corporation Pyrazolopyrimidines as cyclin dependent kinase inhibitors
EP1537116B1 (en) * 2002-09-04 2010-06-02 Schering Corporation Pyrazolopyrimidines suitable for the treatment of cancer diseases
US7196078B2 (en) * 2002-09-04 2007-03-27 Schering Corpoartion Trisubstituted and tetrasubstituted pyrazolopyrimidines as cyclin dependent kinase inhibitors
EP1608652A1 (en) * 2003-03-31 2005-12-28 Vernalis (Cambridge) Limited Pyrazolopyrimidine compounds and their use in medicine
PE20051089A1 (es) * 2004-01-22 2006-01-25 Novartis Ag Derivados de pirazolo [1,5-a] pirimidin-7-il-amina como inhibidores de quinasa de proteina
JP5152922B2 (ja) * 2005-10-06 2013-02-27 メルク・シャープ・アンド・ドーム・コーポレーション プロテインキナーゼを阻害するためのピラゾロ［１，５−ａ］ピリミジン誘導体の使用およびプロテインキナーゼを阻害する方法

Also Published As

Publication number Publication date
US20070072881A1 (en) 2007-03-29
EP2069349B1 (en) 2016-06-15
CN101573363B (zh) 2013-03-06
TW200821313A (en) 2008-05-16
CL2007002856A1 (es) 2008-01-18
JP2010505839A (ja) 2010-02-25
WO2008045267A3 (en) 2008-07-31
WO2008045267A2 (en) 2008-04-17
CN101573363A (zh) 2009-11-04
AR063096A1 (es) 2008-12-30
EP2069349A2 (en) 2009-06-17
CA2665127A1 (en) 2008-04-17
US7605155B2 (en) 2009-10-20

Similar Documents

Publication Publication Date Title
PE20080974A1 (es) Nuevas pirozolopirimidinas como inhibidores de quinasa dependientes de ciclina
PE20070496A1 (es) Compuestos derivados de pirazolopirimidinas como inhibidores de quinasas dependientes de ciclina
CY2020006I2 (el) Ενωσεις υποκατεστημενης πυραζολο [1,5-] πυριμιδινης ως αναστολεις κινασης trk
CL2011001152A1 (es) Compuesto cristalino 6-((s)-1-(6-(1-metil-1h-pirazol-4-il)-[1,2,4]triazolo[3,4-b][1,3,4]tiadiazol-3-il)etil)quinolina, inhibidor de la proteina kinasa c-met; composicion farmaceutica; y metodo para tratar o disminuir la gravedad de un trastorno proliferativo tal como cancer metastasico de colon, mama y hepatico, entre otros.
PE20090156A1 (es) Nuevas pirazolopirimidinas como inhibidores de quinasas dependientes de ciclinas
PE20090964A1 (es) Derivados de pirrolo[2,3-d]pirimidina como inhibidores de proteina quinasa b
MX2009009415A (es) Compuestos de tetrahidroisoquinolina como moduladores del receptor h3 de la histamina.
CL2008003846A1 (es) Uso de compuestos derivados de 1,2,4-triazolo condensado con heterociclos, los cuales actuan como ligados del receptor de androgeno (ar); compuestos; proceso de preparacion; composicion farmaceutica y el uso de dichos compuestos para el tratamiento del cancer de prostata.
MX2009010595A (es) Derivados de pirrolopirimidina.
EA201070395A1 (ru) Ингибиторы polo-подобных киназ
CL2008003200A1 (es) Compuestos derivados de tiazol, inhibidores de la proteina quinasas; composicion farmaceutica; y uso para el tratamiento del cancer, tal como cancer de vejiga, de mama y de rinon.
CL2008002097A1 (es) Compuestos derivados de heterociclos condensados sustituidos, inhibidores de cinasa de fosfatidil-inositol-3; composicion farmaceutica; y uso en el tratamiento del cancer.
TN2010000305A1 (en) Pyrrolopyrimidines and pyrrolopyridines
PE20141855A1 (es) Benzotienilo-pirrolotriazinas disustituidas y sus usos
SV2010003463A (es) Compuestos organicos
EA201170252A1 (ru) Амидофеноксиндазолы в качестве ингибиторов c-мет
ECSP088536A (es) DERIVADOS DE PIRIDO-, PIRAZO- Y PIRIMIDO-PIRIMIDINA COMO INHIBIDORES DE mTOR
ECSP088145A (es) Derivados bicíclicos como inhibidores de la cinasa p38
CL2011003052A1 (es) Compuesto 8-(2,4-dimetoxi-pirimidin-5-il)-1-(1-etil-3-metil-1h-pirazol-4-il)-3-metil-1,3-dihidro-imidazo[4,5-c]quinolin-2-ona; su composicion farmaceutica; util en el tratamiento de enfermedades dependientes de la cinasa de lipido y/o de proteina, en el tratamiento de enfermedades proliferativas, tales como tumores y carcinomas de cerebro, riñon, higado, entre otras.
IL213679A0 (en) Pyrimidine compounds as serotonin receptor modulators
DOP2011000129A (es) 1h-imidazol-2-il-piperidin-1-il como inhibidores de cinasa akt y p70 s6
CL2009000957A1 (es) Compuestos derivados de pirrolo[2,3-d]pirimidina; inhibidores de limk2; composicion farmaceutica que los comprende; utiles en el tratamiento del cancer, trastornos inflamatorios, glaucoma, neurodegeneracion, entre otras.
RS20060584A (en) Beta-carbolines useful for treating inflammatory disease
EA200702071A1 (ru) Новые соединения
CR11098A (es) Compuestos de pirido [2,3-d] pirimidina-7-ona como inhibidores de p13k-alfa para el tratamiento del cancer

Legal Events

Date Code Title Description
FC Refusal